source
- Otsuka presents new data to bolster full approval bid for Voyxact in IgA nephropathyOtsuka Pharmaceutical announced that new clinical evidence has been generated for its monoclonal antibody Voyxact, aimed at treating IgA nephropathy, a chronic autoimmune kidney disease. The data,…
- Dimension Capital targets up to $750M for third life-sciences fund after strong portfolio performanceDimension Capital, a New York and San Francisco-based investment firm that blends machine learning with life-science ventures, announced it is launching its third fund. The firm is seeking up to $…